Failure of drugs in late stages of clinical trials has hampered the global DNA repair drugs
market growth. For instance, in April 2017, Veliparib, a product by AbbVie was withdrawn
from both the clinical trial studies. One of the clinical trial study involved the drug’s efficacy
on breast cancer and other for lung cancer. Veliparib was treated with a combination of
chemotherapy for both, lung and breast cancer treatment. Both of the trials were withdrawn at
its third phase. Such failures may hinder the global DNA repair drugs market growth.
High costs of drugs are expected to hinder the global DNA repair drugs market growth.
Manufacturers are focused on offering a highly effective drug, thus investing more into research
and development activities. This factor further adds up into final cost price of the product. For
instance, a Lynparza tablet of 50 mg costs around US$ 32. Such high cost would be an
obstruction in the developing regions such as Africa, Latin America, and Asia-Pacific for the
global DNA repair drugs market growth.
Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/dna-repair-drugs-market-2617
Global DNA Repair Drugs Market Key Players
Some of the major players operating in the global DNA repair drugs market include 4SC AG,
Artios Pharma, Johnson & Johnson Service Inc., GlaxoSmithKline plc, Genentech, Inc., Sierra
Oncology Inc., AstraZeneca, Karyopharm Therapeutics, Jiangsu Hengrui Medicine Co., Ltd., and
Merck KGaA.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-
ready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com